Preoperative Management of Polycythemia Vera Patients

Introduction to Preoperative Optimization

• The National Comprehensive Cancer Network recommends that patients with polycythemia vera require medical clearance and preoperative optimization before elective surgery to minimize the substantial risks of both thrombosis and bleeding 1, 2

Perioperative Risks and Management

• Patients with polycythemia vera face significantly elevated perioperative risks, with 7.7% experiencing vascular occlusion and 7.3% suffering major hemorrhage, even with optimal management 3, 4
• The American College of Cardiology equivalent guidelines suggest maintaining hematocrit <45% through phlebotomy and/or cytoreductive therapy to reduce the risk of thrombosis 1, 2
• Additional phlebotomy may be necessary immediately before surgery to ensure hematocrit remains <45% 5, 6

Preoperative Requirements

• For elective surgery, hematocrit must be controlled for 3 months prior to the procedure, with normalization or near-normalization of complete blood count without causing prohibitive cytopenias 5, 6
• Initiate or optimize cytoreductive therapy if not already done 1, 2

Multidisciplinary Team Assessment

• Multi-disciplinary management with surgical and perioperative medical teams is recommended, including comprehensive review of bleeding and thrombosis history and current medication list 1, 2, 7
• The team should include a hematologist/oncologist for disease optimization 1
• A surgeon to assess procedure-specific bleeding risk 1
• An anesthesiologist for perioperative planning 1

Coagulation Assessment and Management

• Coagulation tests to evaluate for acquired von Willebrand disease and other coagulopathies are recommended for patients undergoing high-risk surgical procedures 1, 2, 7
• Discontinue aspirin one week prior to surgery 5, 6
• Restart aspirin 24 hours after surgery or when bleeding risk is acceptable 5, 6
• Withhold anticoagulant therapy based on the half-life/type of agent prior to surgery 5, 6
• Restart anticoagulant therapy after surgery when bleeding risk is acceptable 5, 6

High-Risk Surgical Procedures

• The thrombotic and bleeding risk of the surgical procedure should be strongly considered, particularly for orthopedic and cardiovascular surgery 1, 2, 7
• Extended prophylaxis with low molecular weight heparin (LMWH) should be considered for high-risk procedures 1, 2, 7

Emergency Surgery Considerations

• Emergency surgery should be performed as necessary with close postoperative surveillance for symptoms of arterial or venous thrombosis and bleeding 1, 2, 7

Common Pitfalls to Avoid

• Proceeding with elective surgery without adequate hematologic control substantially increases thrombotic risk, particularly venous thromboembolism 3, 4
• Failing to assess for acquired von Willebrand disease in patients with extreme thrombocytosis can lead to unexpected severe bleeding 1, 2
• Stopping cytoreductive therapy unnecessarily, as hydroxyurea can typically be continued perioperatively 5, 6
• Inadequate thromboprophylaxis for high-risk procedures, as PV patients require extended LMWH prophylaxis for orthopedic and cardiovascular surgeries 1, 7
• Restarting aspirin too early, wait until adequate hemostasis is achieved, typically 24 hours postoperatively 5, 6

Preoperative Optimization Strategies for Polycythemia Vera Patients

Hematocrit Management

• Maintaining a hematocrit < 45 % for at least three months before elective surgery reduces vascular occlusive events, as risks rise when hematocrit exceeds 44 % and cerebral blood flow becomes suboptimal between 46–52 % 8.
• Phlebotomy performed with careful fluid replacement (to prevent hypotension and fluid overload) is recommended, especially in patients with underlying cardiovascular disease 8.

Cytoreductive Therapy

• Initiating or optimizing cytoreductive therapy (e.g., hydroxyurea) before surgery lowers early thrombotic complications compared with phlebotomy alone 9.
• The therapeutic goal is normalization or near‑normalization of the complete blood count (CBC) without inducing prohibitive cytopenias prior to elective procedures 9.

Hematologic Targets (Platelets & White Cells)

• Platelet counts should be brought to normal or near‑normal levels before surgery to mitigate vascular complications 9.
• White‑cell counts likewise should be normalized or near‑normal as part of overall disease control 9.

Coagulation Assessment

• Pre‑operative coagulation testing to screen for acquired von Willebrand disease and other coagulopathies is essential before high‑risk surgeries, particularly when platelet counts are markedly elevated 9.

Anticoagulation Management

• For patients on chronic anticoagulation, peri‑operative management should follow the current American College of Chest Physicians (ACCP) guidelines regarding drug‑specific half‑life and timing of interruption and restart 9.

Multidisciplinary Evaluation

• A mandatory multidisciplinary review—including a hematologist/oncologist, surgeon, and anesthesiologist—should be performed to assess bleeding and thrombosis history and current medication list 9.
• The operating surgeon must evaluate procedure‑specific bleeding risk, with particular attention to orthopedic and cardiovascular operations 9.

Surgical Risk Assessment

• The overall thrombotic and bleeding risk associated with the planned surgical procedure must be thoroughly considered before proceeding 9.
• Orthopedic surgeries and procedures that entail prolonged immobilization are identified as having especially high thrombotic risk 9.

Emergency Surgery Considerations

• When emergency surgery is unavoidable, close postoperative surveillance for arterial or venous thrombosis and bleeding is required 9.
• Because the standard three‑month hematologic optimization cannot be achieved in emergencies, heightened vigilance for complications is advised 9.

Fluid Management During Phlebotomy

• Adequate and monitored fluid replacement during phlebotomy is necessary to avoid both hypotension and fluid overload, supporting hemodynamic stability 8.